BR0318503A - quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase - Google Patents

quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase

Info

Publication number
BR0318503A
BR0318503A BRPI0318503-6A BR0318503A BR0318503A BR 0318503 A BR0318503 A BR 0318503A BR 0318503 A BR0318503 A BR 0318503A BR 0318503 A BR0318503 A BR 0318503A
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
protein tyrosine
enzyme inhibitors
kinase enzyme
substituted quinolines
Prior art date
Application number
BRPI0318503-6A
Other languages
English (en)
Inventor
Allan Wissner
Sridhar Krishna Rabindran
Hwei-Ru Tsou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0318503(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0318503A publication Critical patent/BR0318503A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"QUINOLINAS SUBSTITUìDAS COMO INIBIDORES DE ENZIMA PROTEìNA TIROSINA CINASE". A presente invenção refere-se aos compostos de fórmula (I), contendo uma estrutura em que R~ 1~, R~ 2~, R~ 3~ são descritos na especificação. Os compostos agem como agentes anticâncer por inibição de HER-2 e EGFR.
BRPI0318503-6A 2003-09-15 2003-10-15 quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase BR0318503A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15
PCT/US2003/032612 WO2005034955A1 (en) 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR0318503A true BR0318503A (pt) 2006-09-12

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318503-6A BR0318503A (pt) 2003-09-15 2003-10-15 quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase

Country Status (7)

Country Link
EP (1) EP1670473A1 (pt)
AU (1) AU2003304497B2 (pt)
BR (1) BR0318503A (pt)
CA (1) CA2537978C (pt)
MX (1) MXPA06002846A (pt)
UA (1) UA85394C2 (pt)
WO (1) WO2005034955A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0610147A2 (pt) * 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
MX2008013212A (es) * 2006-04-14 2008-10-22 Astrazeneca Ab 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101723854A (zh) 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (zh) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-氰基-6-氨基喹啉类衍生物、其制备方法及其在医药上的应用
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102731395B (zh) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 抗肿瘤药物来那替尼的中间体及其制备与应用
WO2013108754A1 (ja) 2012-01-17 2013-07-25 アステラス製薬株式会社 ピラジンカルボキサミド化合物
CN104926669A (zh) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 反式-4-二甲基胺基巴豆酸盐酸盐的制备方法
CN109422755B (zh) * 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN114920695B (zh) * 2022-06-29 2023-06-20 深圳大学总医院 一种喹唑啉衍生物及其制备方法、药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
IL161921A0 (en) * 2001-11-27 2005-11-20 Wyeth Corp 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Also Published As

Publication number Publication date
AU2003304497B2 (en) 2010-06-24
AU2003304497A1 (en) 2005-04-27
WO2005034955A1 (en) 2005-04-21
CA2537978A1 (en) 2005-04-21
UA85394C2 (ru) 2009-01-26
MXPA06002846A (es) 2006-06-14
EP1670473A1 (en) 2006-06-21
CA2537978C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
BRPI0409164A (pt) pirazóis substituìdos
BRPI0413934A (pt) compostos orgánicos
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
ATE554087T1 (de) Neue kinaseinhibitoren
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
SE0101675D0 (sv) Novel composition
EA200601100A1 (ru) 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
CO5601019A2 (es) Polimorfo del clohidrato de la [6,7-bis(2-metoxi-etoxi)-quinazolin-4-il]-(3-etinil-fenil) amina
BR0213185A (pt) Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BRPI0407913A (pt) antagonistas receptores de ccr-3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/4706, C07D 215/54, C07D 401/12, C07D 417/12, C07D 407/12, C07D 413/12, C07D 405/12, C07D 409/12, A61K 31/4709, A61K 31/506, A61P 35/00

Ipc: A61K 31/4706 (2011.01), C07D 215/54 (2011.01), C07

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.004187/2021-24 ORIGEM: 31O VF DO RIO DE JANEIRO PROCESSO NO: 5031286-04.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: LIBBS FARMACEUTICA LTDA. REU(S): WYETH (US) E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.011680/2021-09 ORIGEM: 21A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1080400-66.2021.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: WYETH LLC REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL